Saborido-Cansino Carmen, Santos-Ramos Bernardo, Carmona-Saucedo Carmen, Rodríguez-Romero María Victoria, González-Martín Antonio, Palma-Amaro Ana, Rojas-Lucena Isabel María, Almeida-González Carmen, Sánchez-Fidalgo Susana
Servicio de Farmacia, Área de Gestión Sanitaria Sur, Sevilla, España.
Servicio de Farmacia, Hospital Universitario Virgen del Rocío, Sevilla, España.
Aten Primaria. 2019 Jun-Jul;51(6):350-358. doi: 10.1016/j.aprim.2018.02.012. Epub 2018 May 31.
To examine the effects of specific interventions on biosimilar glargine insulin (BGI) prescribing in general practices and to analyse the influence of prescriber and economic impact.
Non randomized controlled study.
General practices in 2 health areas of Seville, intervention and control group.
220 general practices (intervention group) and 100 general practices (control group).
Intervention group received educational seminars on biosimilar drugs, pharmacotherapeutic bulletin and prescribing feedback. The study was carried out from the biosimilar commercialization, October-2015, to February-2016 (pre-intervention) and from February to August 2016 (intervention).
Percentage of patients and DDD with BGI respect to total glargine before and during intervention for both areas were analysed. Physicians have been analysed by subgroups of age, sex, training, type of contract, years of experience and quota.
Both indicators for intervention group were significantly greater than for control group (P<.0005), with a 95% confidence interval (2.5-4.7). The ratio of the percentage of cumulative increase of both variables between areas was 3.73 times higher after the intervention. No differences were found for the evaluated categories of physicians in the intervention group.
Intervention strategies aimed at training and information, as well as monitoring health professionals, influence the pattern of prescription and can have an economic impact. Our results have not been influenced by the profile of the prescriber.
研究特定干预措施对基层医疗中生物类似物甘精胰岛素（BGI）处方的影响，并分析开处方者的影响和经济影响。
非随机对照研究。
塞维利亚两个健康区域的基层医疗，干预组和对照组。
220家基层医疗单位（干预组）和100家基层医疗单位（对照组）。
干预组接受了关于生物类似物药物的教育研讨会、药物治疗公报和处方反馈。研究从生物类似物商业化的2015年10月至2016年2月（干预前）以及2016年2月至8月（干预期间）进行。
分析了两个区域干预前和干预期间使用BGI的患者百分比和限定日剂量（DDD）相对于总甘精胰岛素的情况。按年龄、性别、培训、合同类型、经验年限和配额对医生进行了亚组分析。
干预组的两个指标均显著高于对照组（P<0.0005），95%置信区间为（2.5 - 4.7）。干预后两个区域变量累积增加百分比的比率高出3.73倍。干预组中评估的医生类别未发现差异。
旨在培训和提供信息以及监测卫生专业人员的干预策略会影响处方模式并可能产生经济影响。我们的结果未受开处方者特征的影响。
